• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    MetaVia Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    6/30/25 4:05:12 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MTVA alert in real time by email
    0001638287false00016382872025-06-302025-06-30

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

    ​

    FORM 8-K

    ​

    CURRENT REPORT

    ​

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    ​

    Date of Report (Date of earliest event reported): June 30, 2025

    Graphic

    METAVIA INC.

    (Exact name of Registrant as Specified in Its Charter)

    ​

    ​

    ​

    ​

    ​

    ​

    Delaware

    ​

    001-37809

    ​

    47-2389984

    (State or other jurisdiction

    of incorporation)

    ​

    (Commission

    File Number)

    ​

    (IRS Employer

    Identification No.)

    ​

    ​

    ​

    ​

    ​

    ​

    545 Concord Avenue, Suite 210

    Cambridge, Massachusetts

    ​

    ​

    02138

    (Address of principal executive offices)

    ​

    (Zip Code)

    ​

    (857) 702-9600

    (Registrant’s telephone number, including area code)

    ​

    Not applicable

    (Former name or former address, if changed since last report)

    ​

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ​

    ​

    ​

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    ​

    Securities registered pursuant to Section 12(b) of the Act:

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    Title of each class

        

    Trading

    Symbol(s)

        

    Name of each exchange on which registered

    Common Stock, par value $0.001 per share

     

    MTVA

     

    The Nasdaq Stock Market LLC

    ​

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    ​

    Emerging growth company ☐

    ​

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

    ​

    ​

    ​

    ​

    ​

    ​

    Item 5.07.Submission of Matters to a Vote of Security Holders.

    On June 30, 2025, MetaVia Inc. (the “Company”) held a virtual annual meeting of stockholders (the “Annual Meeting”). The Company’s stockholders voted on six proposals at the Annual Meeting as set forth below, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on June 10, 2025. There were 15,364,255 shares of common stock, par value $0.001 per share (the “Common Stock”) present and entitled to vote at the Annual Meeting, online or by proxy, which constituted a quorum for the transaction of business. In deciding the proposals at the Annual Meeting, each share of Common Stock represented one vote.

    At the Annual Meeting, the Company’s stockholders voted on the following proposals:

    1.To elect two Class III directors, each to serve a three-year term until the 2028 annual meeting of stockholders and until the election and qualification of such director’s successor, or such director’s earlier death, resignation, or removal (the “Class III Directors Proposal”);
    2.To ratify the appointment of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025;
    3.To approve (on an advisory basis) the compensation of the Company’s named executive officers;
    4.To approve an amendment to the Company’s Third Amended and Restated Certificate of Incorporation, as amended, to effect a reverse split of the Company’s outstanding Common Stock at a ratio in the range of 1-for-5 to 1-for-30 to be determined at the discretion of the Company’s Board of Directors, whereby each outstanding 5 to 30 shares of Common Stock would be combined, converted and changed into one share of the Company’s Common Stock (the “Reverse Stock Split Proposal”);
    5.to approve, pursuant to Nasdaq Listing Rule 5635(b), the issuance of shares of the Company’s Common Stock, in an amount equal to or in excess of 20% of the shares of Common Stock outstanding immediately prior to the issuance of 4,605,162 shares of Common Stock issuable upon the exercise of the Company’s pre-funded warrants, issued in a private placement to Dong-A Socio Holdings Co., Ltd., pursuant to a Securities Purchase Agreement, dated May 8, 2025, entered into by and among the Company and the purchasers named therein (the “Issuance Proposal”); and
    6.To authorize one or more adjournments of the Annual Meeting to solicit additional proxies in the event there are insufficient votes to approve Proposal 5 described above (the “Adjournment Proposal”).

    The voting results at the Annual Meeting are shown below:

    Proposal 1—The Class III Directors Proposal.

    Class III Nominees

        

    Votes For

        

    Votes Withheld

        

    Mark A. Glickman

      

    15,143,768

    ​

    220,487

    ​

    ​

    Michael Salsbury

      

    15,148,736

    ​

    215,519

    ​

    ​

    ​Mark A. Glickman and Michael Salsbury were elected as Class III directors to serve until the 2028 annual meeting of stockholders. There were no broker non-votes on this matter.

    Proposal 2—Ratification of the appointment of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.

    Votes For

        

    Votes Against

        

    Abstentions

    15,200,517

    ​

    39,673

    ​

    124,065

    ​The stockholders ratified the appointment of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. There were no broker non-votes on this matter.

    Proposal 3—Approval (on an advisory basis) of the compensation of our named executive officers.

    Votes For

        

    Votes Against

        

    Abstentions

    ​

    15,128,182

    ​

    93,199

    ​

    142,874

    ​

    The stockholders approved, on a non-binding advisory basis, the compensation paid by the Company to its named executive officers. There were no broker non-votes on this matter.

    Proposal 4—The Reverse Stock Split Proposal.

    ​

    Votes For

        

    Votes Against

        

    Abstentions

    ​

    15,160,143

    ​

    82,570

    ​

    121,542

    ​

    The stockholders approved the Reverse Stock Split Proposal. There were no broker non-votes on this matter.

    Proposal 5—The Issuance Proposal.

    ​

    Votes For

        

    Votes Against

        

    Abstentions

    ​

    5,643,798

    ​

    99,638

    ​

    141,474

    ​

    The stockholders approved the Issuance Proposal. There were no broker non-votes on this matter.

    Proposal 6—The Adjournment Proposal.

    ​

    Votes For

        

    Votes Against

        

    Abstentions

    ​

    15,130,972

    ​

    91,911

    ​

    141,372

    ​

    The stockholders approved the Adjournment Proposal. There were no broker non-votes on this matter.

    ​

    ​

    ​

    SIGNATURES

    ​

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    ​

    ​

    ​

    ​

    ​

    ​

        

    METAVIA INC.

    ​

    ​

    ​

    ​

    ​

    ​

    Date: June 30, 2025

    ​

    By:

    /s/ Hyung Heon Kim

    ​

    ​

    ​

    Hyung Heon Kim

    ​

    ​

    ​

    President and Chief Executive Officer

    ​

    ​

    ​

    Get the next $MTVA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MTVA

    DatePrice TargetRatingAnalyst
    9/4/2025$12.00Buy
    H.C. Wainwright
    12/30/2024$12.00Buy
    H.C. Wainwright
    More analyst ratings

    $MTVA
    SEC Filings

    View All

    MetaVia Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - MetaVia Inc. (0001638287) (Filer)

    4/10/26 8:45:31 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by MetaVia Inc.

    424B3 - MetaVia Inc. (0001638287) (Filer)

    4/7/26 4:01:44 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by MetaVia Inc.

    EFFECT - MetaVia Inc. (0001638287) (Filer)

    4/7/26 12:15:05 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTVA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Woodworth Marshall H was granted 28,000 shares, increasing direct ownership by 1,024% to 30,734 units (SEC Form 4)

    4 - MetaVia Inc. (0001638287) (Issuer)

    1/27/26 4:02:10 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO & President Kim Hyung Heon was granted 32,000 shares, increasing direct ownership by 577% to 37,545 units (SEC Form 4)

    4 - MetaVia Inc. (0001638287) (Issuer)

    1/27/26 4:01:16 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Woodworth Marshall H gifted 14,200 shares, decreasing direct ownership by 32% to 30,079 units (SEC Form 4)

    4 - MetaVia Inc. (0001638287) (Issuer)

    8/13/25 4:36:41 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTVA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Woodworth Marshall H bought $9,940 worth of shares (14,200 units at $0.70), increasing direct ownership by 47% to 44,279 units (SEC Form 4)

    4 - MetaVia Inc. (0001638287) (Issuer)

    6/4/25 4:01:12 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Dong-A St Co., Ltd bought $3,300,000 worth of shares (4,647,887 units at $0.71), increasing direct ownership by 87% to 9,995,679 units (SEC Form 4)

    4 - MetaVia Inc. (0001638287) (Issuer)

    5/20/25 4:16:39 PM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTVA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity

    16-Week Study Evaluates One-Step Dose Titration to 48 mg and Two-Step Dose Titration to 64 mg in Obese Otherwise Healthy AdultsCAMBRIDGE, Mass., April 10, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that the first patient has been dosed in Part 3 of its Phase 1 clinical trial evaluating DA-1726, a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors. Part 3 of the Phase 1 program consists of two 16-week titration cohorts designed to evaluate one-step and two-step dose-escalation strategies to safely achieve higher target doses and further o

    4/10/26 8:30:00 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update

    48 mg Phase 1 Data Demonstrate Potential Best-in-Class Profile for DA-1726 with 9.1% Weight Loss, Improved Glucose Control and Direct Liver Benefit Planned Phase 1 Part 3 16-Week Titration Study to Evaluate 48 mg (1-Step) and 64 mg (2-Step) Regimen Receives IRB Approval; Initiation Expected in April of 2026 with Data Anticipated in the Fourth Quarter $10.3 Million in Cash and Cash Equivalents at End of Year and Proceeds From January 2026 Public Offering is Expected to Fund the Company Into the Fourth Quarter of 2026CAMBRIDGE, Mass., March 26, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announc

    3/26/26 8:31:00 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control

    16-Week Study to Evaluate One-Step Dose Titration to 48 mg and Two-Step Dose Titration to 64 mg in Obese Otherwise Healthy AdultsCAMBRIDGE, Mass., March 18, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that the Institutional Review Board (IRB) at Clinical Pharmacology of Miami has approved the Company's Phase 1 Part 3 clinical trial of its lead asset, DA-1726, a novel, dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors. The approval enables initiation of Part 3 of the Phase 1 program, which consists of two 16-week titration cohorts evaluating on

    3/18/26 8:00:00 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTVA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on MetaVia with a new price target

    H.C. Wainwright resumed coverage of MetaVia with a rating of Buy and set a new price target of $12.00

    9/4/25 9:02:00 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on MetaVia with a new price target

    H.C. Wainwright initiated coverage of MetaVia with a rating of Buy and set a new price target of $12.00

    12/30/24 7:25:48 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MTVA
    Leadership Updates

    Live Leadership Updates

    View All

    MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum

    CAMBRIDGE, Mass., March 4, 2026 /PRNewswire/ -- MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer, will participate in a fireside chat highlighting the company's pipeline of novel obesity and metabolic therapies at the Life Sciences Virtual Investor Forum, co-hosted by Zacks Small Cap Research, on Thursday, March 12, 2026 at 10:30 am ET. This will be a live, interactive online event where investors are invited to ask the company questions

    3/4/26 8:31:00 AM ET
    $MTVA
    Biotechnology: Pharmaceutical Preparations
    Health Care